Webinar Overview

Several high-profile cases regarding changes to off-label prescribing have recently arisen in France and Italy. At first glance it appears that recent changes are targeted foremost to ratify Lucentis as an alternative for Avastin in wet AMD (age-related macular degeneration), but legislation extends wider than this as a means to facilitate cost containment in potentially several therapy areas. In this webinar, we discuss what we actually know about off-label use, what routes payers have already taken to utilize off-label policies, the potential these have for wider use across Europe and the potential impact of these changes from market access, HTA, and regulatory perspectives.

Who Should Attend

  • Pricing and Market Access Directors
  • Commercial Planning Directors
  • Brand Team Directors
  • HEOR Directors
  • Marketing Directors
  • Business Development Directors
  • New Product Planning Directors
  • Regulatory Director

Key Learning Objectives

  • Understand current dynamics and payer positions on off-label policies in Europe
  • Understand the likelihood of further changes to promote cost-containment
  • Understand implications of off-label policies for launched and future products



Susanne Michel, MD, Europe Practice Lead, Payer Strategy; Catherine Bennett, MSc, Senior Consultant, Payer Strategy